Cargando…
Mepolizumab in the treatment of eosinophilic chronic obstructive pulmonary disease
Despite maximal medical therapy, a subset of patients with chronic obstructive pulmonary disease continue to suffer acute exacerbations. It is also clear that a subset of this population has elevated blood eosinophils. In addition to clearly responding better to inhaled corticosteroids, it is also p...
Autores principales: | Mkorombindo, Takudzwa, Dransfield, Mark T |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6689550/ https://www.ncbi.nlm.nih.gov/pubmed/31496677 http://dx.doi.org/10.2147/COPD.S162781 |
Ejemplares similares
-
The Air We Breathe: Respiratory Impact of Indoor Air Quality in Chronic Obstructive Pulmonary Disease
por: Mkorombindo, Takudzwa, et al.
Publicado: (2022) -
Case Report: Mepolizumab in the treatment of idiopathic chronic eosinophilic pneumonia
por: Daboussi, Selsabil, et al.
Publicado: (2023) -
Impact of Quality Improvement on Care of Chronic Obstructive Pulmonary Disease Patients in an Internal Medicine Resident Clinic
por: Burkes, Robert M., et al.
Publicado: (2018) -
Clinical usefulness of mepolizumab in severe eosinophilic asthma
por: Menzella, Francesco, et al.
Publicado: (2016) -
From DREAM to REALITI‐A and beyond: Mepolizumab for the treatment of eosinophil‐driven diseases
por: Pavord, Ian D., et al.
Publicado: (2021)